### Panel Discussion

**AML-11**  
Internal request: Review the category designation for hypomethylating agents (5-azacytidine, decitabine) across all performance statuses for patients aged \( \geq 60 \) years.

Based upon the data in the noted references, the panel consensus was to change the category designation for hypomethylating agents (5-azacytidine, decitabine) from a category 2B to a category 2A for patients with a performance status 0-2.


**AML-12**  
Internal request: Review the category designation for hypomethylating agents (5-azacytidine, decitabine) across all performance statuses for patients aged \( \geq 60 \) years.

Based upon the data in the noted references, the panel consensus was to change the category designation for hypomethylating agents (5-azacytidine, decitabine) from a category 2B to a category 2A for patients with a performance status > 2.


**AMF-F**  
Internal request: Suggest adding clofarabine + cytarabine + GCSF as a salvage chemotherapy regimen option.

Based upon the data in the noted reference, the panel consensus was to add clofarabine + cytarabine + GCSF as a salvage chemotherapy regimen option.


### Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>16</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>15</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
### Panel Discussion

Based upon the data in the noted references, the panel consensus was to add low dose cytarabine or hypomethylating agents (5-azacytidine, decitabine) as induction therapy for patients with significant comorbidities and as salvage chemotherapy regimen options for patients not able to tolerate aggressive regimens.

### References